Drugs / Ferulic Acid
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial · 1 met primary | ||||||
| Phase 1 | NCT05736224 | May → Sep 2023 | skin cancer | Yale University | Completed | Met primary |
| Phase 21 trial | ||||||
| Phase 2 | NCT06170346 | Nov 2022 → Jul 2023 | — | Padjadjaran University | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT07404072 Comparator | May 2025 → Jan 2026 overdue | periodontitis | Salah Awad Alanazi | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ferulic acid | “30 drops of topical antioxidants (Gluconolactone 4%, Hyaluronic acid 0,01%, Allantoin 0,1%, Ferulic acid 3%, Acetyl heptapeptide 0,001%, Silver vine extract 1%, Ectoine 0,01%,...” NCT06170346 ↗2“The sunscreen contains bioadhesive nanoparticles (BNP) encapsulating avobenzone and octocrylene plus the non-toxic natural products diosmin, ferulic acid, cytisine and...” NCT05736224 ↗ |
| Known as | 4-hydroxy-3-methoxycinnamic acid | “Ferulic acid, known as 4-hydroxy-3-methoxycinnamic acid, is a phenolic compound naturally found in various plants, including cereals, fruits, vegetables, and Chinese herbal medicines.” NCT07404072 ↗ |
| Modality | Small molecule | “Ferulic acid, known as 4-hydroxy-3-methoxycinnamic acid, is a phenolic compound” NCT07404072 ↗ |
| Route | Topical | “30 drops of topical antioxidants (Gluconolactone 4%, Hyaluronic acid 0,01%, Allantoin 0,1%, Ferulic acid 3%, Acetyl heptapeptide 0,001%, Silver vine extract 1%, Ectoine 0,01%,...” NCT06170346 ↗ |